CN109844130B - 细胞vamp切割测定 - Google Patents

细胞vamp切割测定 Download PDF

Info

Publication number
CN109844130B
CN109844130B CN201780063220.0A CN201780063220A CN109844130B CN 109844130 B CN109844130 B CN 109844130B CN 201780063220 A CN201780063220 A CN 201780063220A CN 109844130 B CN109844130 B CN 109844130B
Authority
CN
China
Prior art keywords
bont
vamp
antibody
seq
cleavage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780063220.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109844130A (zh
Inventor
B·格雷
V·加德
M·比尔得
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharm Ltd
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Priority to CN202411324418.8A priority Critical patent/CN119529053A/zh
Publication of CN109844130A publication Critical patent/CN109844130A/zh
Application granted granted Critical
Publication of CN109844130B publication Critical patent/CN109844130B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN201780063220.0A 2016-10-18 2017-10-18 细胞vamp切割测定 Active CN109844130B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411324418.8A CN119529053A (zh) 2016-10-18 2017-10-18 细胞vamp切割测定

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16194390.7A EP3312290A1 (en) 2016-10-18 2016-10-18 Cellular vamp cleavage assay
EP16194390.7 2016-10-18
PCT/EP2017/076569 WO2018073288A1 (en) 2016-10-18 2017-10-18 Cellular vamp cleavage assay

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411324418.8A Division CN119529053A (zh) 2016-10-18 2017-10-18 细胞vamp切割测定

Publications (2)

Publication Number Publication Date
CN109844130A CN109844130A (zh) 2019-06-04
CN109844130B true CN109844130B (zh) 2024-10-11

Family

ID=57208094

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411324418.8A Pending CN119529053A (zh) 2016-10-18 2017-10-18 细胞vamp切割测定
CN201780063220.0A Active CN109844130B (zh) 2016-10-18 2017-10-18 细胞vamp切割测定

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202411324418.8A Pending CN119529053A (zh) 2016-10-18 2017-10-18 细胞vamp切割测定

Country Status (5)

Country Link
US (2) US11193931B2 (enExample)
EP (2) EP3312290A1 (enExample)
JP (3) JP7127019B2 (enExample)
CN (2) CN119529053A (enExample)
WO (1) WO2018073288A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088381A2 (en) 2010-12-22 2012-06-28 President And Fellows Of Harvard College Continuous directed evolution
US10179911B2 (en) 2014-01-20 2019-01-15 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
WO2016077052A2 (en) 2014-10-22 2016-05-19 President And Fellows Of Harvard College Evolution of proteases
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
PL3481852T3 (pl) * 2016-07-08 2023-07-24 Children's Medical Center Corporation Nowa neurotoksyna botulinowa i jej pochodne
EP3312290A1 (en) * 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
WO2018081282A1 (en) * 2016-10-25 2018-05-03 Cellsnap Llc Neurotoxins and uses thereof
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
WO2019040935A1 (en) 2017-08-25 2019-02-28 President And Fellows Of Harvard College EVOLUTION OF PEPTIDASES BONT
WO2019056002A1 (en) 2017-09-18 2019-03-21 President And Fellows Of Harvard College CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
EP3752128B1 (de) * 2018-02-16 2025-01-15 preclinics discovery GmbH Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
US11913044B2 (en) 2018-06-14 2024-02-27 President And Fellows Of Harvard College Evolution of cytidine deaminases
KR102017240B1 (ko) 2018-08-23 2019-09-02 주식회사 하울바이오 Snare 복합체를 억제하는 항-vamp2 항체 및 이의 용도
US20220259269A1 (en) * 2019-07-15 2022-08-18 President And Fellows Of Harvard College Evolved botulinum neurotoxins and uses thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
US7227010B2 (en) * 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
SE9304060D0 (sv) 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager
US5962637A (en) * 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
GB9411138D0 (en) * 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
GB9500851D0 (en) 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
AU2334897A (en) * 1996-03-18 1997-10-10 Regents Of The University Of California, The Peptide inhibitors of neurotransmitter secretion by neuronal cells
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
FR2809733B1 (fr) * 2000-06-02 2004-04-30 Inst Nat Sante Rech Med Substrat peptidique reconnu par la toxine botulique de type bont/b et son utilisation pour doser et/ou detecter ladite toxine ou des inhibiteurs correspondants
AU2002228887B2 (en) * 2000-11-06 2006-08-24 United States Army Medical Research And Material Command Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
GB0115581D0 (en) * 2001-06-26 2001-08-15 Glaxo Group Ltd Method of mass spectometry
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
US7611856B2 (en) * 2003-11-05 2009-11-03 Los Alamos National Security, Llc Mass spectrometry-based methods for detection and differentiation of botulinum neurotoxins
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
EP1784420B1 (en) 2004-09-01 2008-12-03 Allergan, Inc. Degradable clostridial toxins
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
GB0425795D0 (en) 2004-11-24 2004-12-22 Givaudan Sa Composition
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
EP1877073B1 (en) 2004-12-01 2013-09-25 The Secretary of State for Health Non-cytotoxic protein conjugates
US8052979B2 (en) 2005-03-15 2011-11-08 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ATE463506T1 (de) 2005-09-19 2010-04-15 Allergan Inc Mit clostriedientoxin aktivierbare clostridientoxine
CA2601537A1 (en) 2006-03-14 2007-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US8753831B2 (en) * 2007-06-05 2014-06-17 City Of Hope Methods for detection of botulinum neurotoxin
US9303284B2 (en) * 2007-09-14 2016-04-05 Biomadison, Inc. Resonance energy transfer assay with cleavage sequence and spacer
US8940477B2 (en) * 2007-11-08 2015-01-27 Wisconsin Alumni Research Foundation Method of detecting botulinum neurotoxin and antibodies that neutralize botulinum neurotoxin action
JP5728380B2 (ja) 2008-06-12 2015-06-03 シンタクシン リミテッドＳｙｎｔａｘｉｎ Ｌｉｍｉｔｅｄ 神経内分泌疾患の抑制
CA2726092A1 (en) 2008-06-12 2009-12-17 Syntaxin Limited Suppression of cancers
GB0815264D0 (en) 2008-08-21 2008-09-24 Syntaxin Ltd Non-cytotoxic proteins
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US20100303791A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303783A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303788A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
AU2010282276A1 (en) 2009-08-14 2012-03-15 Allergan, Inc. Methods of treating cancer using neurotrophin retargeted endopeptidases
CA2771154A1 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using opioid retargeted endpeptidases
US20110070212A1 (en) 2009-08-14 2011-03-24 Allergan, Inc. Methods of Treating Cancer Using Glucagon-Like Hormone Retargeted Endopeptidases
AU2010282289A1 (en) 2009-08-14 2012-03-15 Allergan, Inc. Methods of treating cancer using galanin retargeted endpeptidases
KR20120061878A (ko) 2009-08-14 2012-06-13 알러간, 인코포레이티드 타키키닌 재표적화된 엔도펩티다아제를 사용하여 암을 치료하는 방법
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120258132A1 (en) 2011-03-29 2012-10-11 Allergan, Inc. Vagal Nerve-Based Disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US20140287433A1 (en) * 2011-07-19 2014-09-25 ETH Zürich Means and methods for determining clostridial neurotoxins
EP2734635A1 (en) * 2011-07-19 2014-05-28 ETH Zürich Means and methods for determining clostridial neurotoxins
RU2616281C2 (ru) * 2011-09-29 2017-04-13 СЕЛЛСНЭП, ЭлЭлСи Композиции и способы испытаний на токсикогенность
EP3372239B1 (en) 2012-05-30 2020-11-11 President and Fellows of Harvard College Engineered botulinum neurotoxin
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
WO2014079878A1 (en) * 2012-11-21 2014-05-30 Merz Pharma Gmbh & Co. Kgaa Means and methods for determination of botulinum neurotoxin biological activity
GB201303108D0 (en) 2013-02-21 2013-04-10 Syntaxin Ltd Therapeutics for suppressing osteoporosis
ES2699432T3 (es) * 2013-06-28 2019-02-11 Merz Pharma Gmbh & Co Kgaa Medios y métodos para la determinación de la actividad biológica de polipéptidos de neurotoxinas en células
GB201312295D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Suppression of itch
EP3312290A1 (en) * 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Development of an in vitro bioassay for Clostridium botulinum type B neurotoxin in foods that is more sensitive than the mouse bioassay;M Wictome等;《Appl Environ Microbiol.》;19990930;第65卷(第9期);第3787-3792页 *

Also Published As

Publication number Publication date
RU2019113794A3 (enExample) 2021-09-10
US20190219575A1 (en) 2019-07-18
US20220113310A1 (en) 2022-04-14
CN119529053A (zh) 2025-02-28
EP3312290A1 (en) 2018-04-25
JP2019537567A (ja) 2019-12-26
WO2018073288A1 (en) 2018-04-26
US12493035B2 (en) 2025-12-09
EP3529370A1 (en) 2019-08-28
JP7656571B2 (ja) 2025-04-03
JP2022130378A (ja) 2022-09-06
CN109844130A (zh) 2019-06-04
RU2019113794A (ru) 2020-11-20
JP2024123229A (ja) 2024-09-10
US11193931B2 (en) 2021-12-07
JP7127019B2 (ja) 2022-08-29

Similar Documents

Publication Publication Date Title
JP7656571B2 (ja) 細胞性ｖａｍｐ切断アッセイ
US11332518B2 (en) Immuno-based botulinum toxin serotype A activity assays
US10900967B2 (en) Immuno-based retargeted endopeptidase activity assays
TWI632369B (zh) 用於測定細胞中神經毒素多肽之生物活性的工具及方法
US8618261B2 (en) Immuno-based botulinum toxin serotype A activity assays
RU2807994C2 (ru) Анализ расщепления клеточного vamp
HK40008973B (zh) 细胞vamp切割测定
HK40008973A (en) Cellular vamp cleavage assay
HK1169855B (en) Immuno-based retargeted endopeptidase activity assays
AU2017210625A1 (en) Immuno-based botulinum toxin serotype A activity assays
HK1151298B (en) Immuno-based botulinum toxin serotype a activity assays

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40008973

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment